Quick Answer
PLIANT THERAPEUTICS, INC. reported Operating Income Loss of -$156.37 million for the year ending 2025.
- PLIANT THERAPEUTICS, INC. showed an increase of +31.5% in Operating Income Loss from 2024 to 2025.
- This data is from PLIANT THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: -$15.74 million | Q3 2019: -$13.36 million | Q1 2020: $11.01 million | Q2 2020: -$16.98 million | Q3 2020: -$16.66 million | Q1 2021: -$22.92 million | Q2 2021: -$22.90 million | Q3 2021: -$27.11 million | Q1 2022: -$28.21 million | Q2 2022: -$29.64 million | Q3 2022: -$31.95 million | Q1 2023: -$42.10 million | Q2 2023: -$47.33 million | Q3 2023: -$47.69 million | Q1 2024: -$52.39 million | Q2 2024: -$60.64 million | Q3 2024: -$62.01 million | Q1 2025: -$58.94 million | Q2 2025: -$45.59 million | Q3 2025: -$28.27 million.
- Over the full 7 years of available data (2019 to 2025), PLIANT THERAPEUTICS, INC.'s Operating Income Loss has declined by 12,602.9%.
- Historical annual values: Fiscal year 2025: -$156.37 million | Fiscal year 2024: -$228.37 million | Fiscal year 2023: -$184.15 million | Fiscal year 2022: -$127.20 million | Fiscal year 2021: -$97.54 million | Fiscal year 2020: -$41.65 million | Fiscal year 2019: -$1.23 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: